Last reviewed · How we verify
Bone modifying agent
Bone modifying agents alter bone remodeling by inhibiting osteoclast activity or promoting osteoblast function to increase bone density and reduce fracture risk.
Bone modifying agents alter bone remodeling by inhibiting osteoclast activity or promoting osteoblast function to increase bone density and reduce fracture risk. Used for Osteoporosis prevention and treatment, Bone loss associated with various conditions.
At a glance
| Generic name | Bone modifying agent |
|---|---|
| Also known as | Zoledronate, Denosumab, Pamidronate |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Bone modifying agent |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
These agents work by targeting the balance between bone resorption and formation. Common mechanisms include inhibition of osteoclast-mediated bone resorption (e.g., bisphosphonates, denosumab) or stimulation of osteoblast-mediated bone formation. By shifting this balance toward bone formation or reducing excessive resorption, they increase bone mineral density and mechanical strength.
Approved indications
- Osteoporosis prevention and treatment
- Bone loss associated with various conditions
Common side effects
- Osteonecrosis of the jaw
- Atypical fractures
- Gastrointestinal upset
Key clinical trials
- Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial (PHASE3)
- Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (PHASE4)
- Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease (PHASE2)
- A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bone modifying agent CI brief — competitive landscape report
- Bone modifying agent updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI